Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.
AuthorsMoore, James V
Waller, Michael L
Dodd, Nicholas J F
Acton, P D
Jeavons, A P
Hastings, D L
AffiliationPaterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.
MetadataShow full item record
AbstractOne early effect of the treatment of tumours by the new modality photodynamic therapy (PDT) is a reduction in tumour glucose levels. We have employed the widely used positron-emitting glucose analogue flurorine-18 fluoro-2-deoxy-D-glucose ([18F]-FDG), to determine whether, in principle, PDT-induced injury might be delineated non-invasively and quantitatively by positron emission tomography (PET). The scanner was of the high-density avalanche-chamber (HIDAC) type with a resolution of 2.6 mm. Subcutaneous T50/80 mouse mammary tumours, sensitised by haematoporphyrin ester, were illuminated by graded doses of interstitial 630 nm light. Thirty hours later, any remaining viable tumour was detected (a) by region-of-interest analysis of the PET images and (b) by gamma counting the excised tumour. PET measurements of % uptake of [18F]-FDG into tumour correlated closely with ex vivo gamma counting (slope=0.976, r2=0. 995), validating the in situ method. Uptake into untreated, control tumours was 3.8%+/-1.1% of the injected activity. Uptake of [18F]-FDG into treated tumours decreased by 0.7% for every 100 mm3 reduction in remaining viable histological volume. Outcome was further compared with that measured by (a) T2-weighted proton imaging on a 4.7-T magnetic resonance imaging (MRI) system and (b) histological analysis of subsequently sectioned tumours. PET using [18F]-FDG described the absolute volume of surviving tumour histological mass to the same degree as high-resolution MRI. The conclusion of these initial studies is that PET with [18F]-FDG, although non-specific, quantitatively described at early times the extent of tumour destruction by PDT.
CitationFeasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography. 1998, 25 (9):1248-54 Eur J Nucl Med
JournalEuropean Journal of Nuclear Medicine
- Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
- Authors: Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF, Wahl RL
- Issue date: 2003 Oct 1
- High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice.
- Authors: Lapointe D, Brasseur N, Cadorette J, La Madeleine C, Rodrigue S, van Lier JE, Lecomte R
- Issue date: 1999 May
- Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose.
- Authors: Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J
- Issue date: 2000
- Deciphering PDT-induced inflammatory responses using real-time FDG-PET in a mouse tumour model.
- Authors: Cauchon N, Hasséssian HM, Turcotte E, Lecomte R, van Lier JE
- Issue date: 2014 Oct
- In vivo magnetic resonance imaging of the effects of photodynamic therapy.
- Authors: Dodd NJ, Moore JV, Poppitt DG, Wood B
- Issue date: 1989 Aug